Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) Director Buys $88,681.60 in Stock

Key Points

  • AgomAb director David Epstein bought 14,980 shares for $88,681.60 at an average price of $5.92, increasing his stake by 37.45% to 54,980 shares.
  • AGMB opened at $5.97, near its 12-month low of $5.73; its 50-day and 200-day moving averages were $9.38 and $11.70, respectively.
  • Analyst sentiment is mostly positive: eight analysts rate the stock Buy and one Hold, giving it a Moderate Buy consensus and an average price target of $37.50.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein purchased 14,980 shares of the stock in a transaction dated Friday, November 13th. The stock was purchased at an average cost of $5.92 per share, for a total transaction of $88,681.60. Following the completion of the acquisition, the director owned 54,980 shares of the company's stock, valued at approximately $325,481.60. This represents a 37.45% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

AgomAb Therapeutics Stock Performance

AGMB stock opened at $5.97 on Tuesday. The firm has a 50 day moving average of $9.38 and a 200-day moving average of $11.70. AgomAb Therapeutics NV has a 12 month low of $5.73 and a 12 month high of $17.82.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating on shares of AgomAb Therapeutics in a research note on Wednesday, October 21st. Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an "overweight" rating and a $60.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an "overweight" rating for the company. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. Finally, Wall Street Zen downgraded AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 27th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $37.50.




Read Our Latest Analysis on AGMB

AgomAb Therapeutics Company Profile

(Get Free Report)

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company's pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn's disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.

Read More

Insider Buying and Selling by Quarter for AgomAb Therapeutics (NASDAQ:AGMB)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at AgomAb Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for AgomAb Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles